Table 1. . Baseline characteristics of 100 patients treated with second-line immunotherapy.
| Characteristic | Patients, n (%) |
|---|---|
| Age, years, mean (SD) | 60 |
| Sex | |
| Female | 51 (51.0%) |
| Male | 49 (49.0%) |
| Smoking status | |
| Smoker | 46 (46.0%) |
| Nonsmoker | 54 (54.0%) |
| Asbestos exposure | |
| Yes | 23 (23.0%) |
| No | 77 (77.0%) |
| ECOG | |
| 0 | 35 (35.0%) |
| 1 | 46 (46.0%) |
| 2 | 18 (18.0%) |
| 3 | 1 (1.0%) |
| Clinical stage at diagnosis | |
| II | 2 (2.0%) |
| III | 7 (7.0%) |
| IV | 91 (91.0%) |
| Diagnosis | |
| Lung adenocarcinoma | 93 (93.0%) |
| Lung squamous cell carcinoma | 7 (7.0%) |
| Immunotherapy treatment | |
| Nivolumab | 70 (70.0%) |
| Pembrolizumab | 7 (7.0%) |
| Atezolizumab | 16 (16.0%) |
| Avelumab | 4 (4.0%) |
| Other | 3 (3.0%) |
| Immunotherapy line number | |
| Second-line treatment | 51 (51.0%) |
| Third-line treatment | 38 (38.0%) |
| Fourth-line treatment | 9 (9.0%) |
| Fifth-line treatment | 2 (2.0%) |
ECOG: Eastern Cooperative Oncology Group; SD: Standard deviation.